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Abstract
Background and objective—About 9% of gastric carcinomas have Epstein–Barr virus (EBV) 
in the tumour cells, but it is unclear whether viral presence influences clinical progression. We 
therefore examined a large multicentre case series for the association of tumour EBV status with 
survival after gastric cancer diagnosis, accounting for surgical stage and other prognostic factors.
Methods—We combined individual-level data on 4599 gastric cancer patients diagnosed 
between 1976 and 2010 from 13 studies in Asia (n=8), Europe (n=3), and Latin America (n=2). 
EBV positivity of tumours was assessed by in situ hybridisation. Mortality HRs for EBV positivity 
were estimated by Cox regression models stratified by study, adjusted for distributions of sex 
(71% male), age (mean 58 years), stage (52% tumour-node-metastasis stages III or IV), tumour 
histology (49% poorly differentiated, 57% Lauren intestinal-type), anatomic subsite (70% non-
cardia) and year of diagnosis. Variations by study and continent were assessed using study-
specific HRs for EBV positivity.
Results—During median 3.0 years follow-up, 49% of patients died. Stage was strongly 
predictive of mortality, with unadjusted HRs (vs stage I) of 3.1 for stage II, 8.1 for stage III and 
13.2 for stage IV. Tumour EBV positivity was 8.2% overall and inversely associated with stage 
(adjusted OR: 0.79 per unit change). Adjusted for stage and other confounders, EBV positivity 
was associated with lower mortality (HR, 0.72; 95% CI 0.61 to 0.86), with low heterogeneity 
among the study populations (p=0.2). The association did not significantly vary across patient or 
tumour characteristics. There was no significant variation among the three continent-specific HRs 
(p=0.4).
Conclusions—Our findings suggest that tumour EBV positivity is an additional prognostic 
indicator in gastric cancer. Further studies are warranted to identify the mechanisms underlying 
this protective association.
INTRODUCTION
Gastric cancer is the second leading cause of cancer-related deaths worldwide.1 Although 
chronic Helicobacter pylori infection is the primary cause of gastric cancer,2 most infected 
individuals never develop this neoplasia, suggesting that progression to cancer may require 
additional co-factors. One possibility may be the Epstein–Barr virus (EBV), a recognised 
carcinogenic agent,3 which is present in tumour cells of about 9% of gastric carcinomas.45 
While the monoclonality6 of viral episomes and the distinct clinicopathological and genetic 
features7 of EBV-positive gastric cancer support the aetiological significance of EBV in 
gastric carcinogenesis, it remains unclear whether tumour viral infection influences clinical 
prognosis.
To further examine associations between EBV and gastric cancer with sufficient statistical 
power, we have assembled individual-level data from multiple international gastric cancer 
case series for aggregated analysis. Here we present findings for the association of tumour 
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We pooled individual-level data of 13 gastric cancer case series from Asia (n=8),8–15 
Europe (n=3)16–18 and Latin America (n=2),1920 including six that have separately 
published data on EBV and survival in one9–111317 or two1421 reports. Ten were unselected 
case series and three101317 were enriched for EBV-positive tumours. On a total of 4599 
patients diagnosed between 1976 and 2010, we included variables that may be related to 
both tumour EBV status and survival after diagnosis: sex, age at diagnosis, tumour–node–
metastasis (TNM) stage (American Joint Committee on Cancer classification, AJCC), 
histological type (Lauren classification), degree of differentiation, anatomic subsite 
(according to the International Classification of Diseases for Oncology) and year of 
diagnosis. Each contributing study received local institutional review board approval, and 
written informed consent was obtained for all study participants.
Tumour EBV detection
For all 13 case series, the presence of EBV in cancer cells was assessed by in situ 
hybridisation for EBV-encoded RNA (EBER), the gold standard assay for detecting latent 
infection.22 For the samples from Shanxi, China (n=1039),8 Poland (n=87),18 and the 
European Prospective Investigation into Cancer and Nutrition cohort (EPIC) (n=87),16 
EBER expression in formalin-fixed paraffin-embedded tumours (as tissue microarrays, with 
inclusion of known EBER-positive and -negative tumours as controls) was detected with an 
automated method, as previously described.23 A tumour was considered EBV-negative if 
EBER staining was undetected or only expressed in benign-appearing lymphoid cells, and 
EBV-positive if EBER staining was localised to the nucleus of malignant epithelial cells.
For the samples from the Hospital-based Epidemiologic Research Program at Aichi Cancer 
Center II, Japan (n=371),12 EBER detection was performed manually on formalin-fixed 
paraffin-embedded sections, using a complementary fluorescein-labelled oligonucleotide 
probe (Dako, Copenhagen, Denmark), according to the manufacturer’s specifications. For 
the remaining case series,9–1113–15171920 EBV presence in tumour cells was previously 
assessed following similar protocols. Validation work has been published showing excellent 
agreement between the manual and automated staining methods described above.23
Statistical analyses
For this aggregated analysis, the endpoint of interest was survival time between gastric 
cancer diagnosis and death from any cause. Follow-up time was censored on the date of 
death or, if death did not occur, on date last known alive. Actuarial (unadjusted) curves were 
constructed using the Kaplan–Meier method and their difference was evaluated by a log-
rank test.
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Complete data were available on age, sex and year of diagnosis. In the main analysis, 
missing values were included as a separate category for TNM stage (6.6%), anatomic subsite 
(9.3%), Lauren histological type (4.9%) and degree of differentiation (6.8%). In a sensitivity 
analysis, we excluded such cases for comparison to the overall dataset.
Unadjusted and multivariable logistic regression models including a study-specific random 
intercept were used to estimate summary OR of gastric cancer EBV positivity in relation to 
age at diagnosis (categorised as quintiles), sex (male vs female), year of diagnosis 
(categorised as quintiles), anatomic subsite (cardia, non-cardia, overlapping subsites, 
unspecified or surgical stump), TNM stage (I, II, III, IV or unspecified), degree of 
differentiation (well, moderate, poor or unspecified) and Lauren histological type (diffuse, 
intestinal, mixed or unspecified). To further understand the potential association of EBV 
positivity and stage, the three individual components of the TNM staging system (ie, 
tumour, lymph nodes and presence of metastases) were also evaluated.
Cox proportional hazard regression models stratified by study were used to estimate 
mortality HRs with 95% CIs. Tumour EBV status and other variables were initially assessed 
for associations with mortality in unadjusted models. Statistically significant variables in 
these individual analyses were included in multivariable models. Given the high correlation 
between histological type and degree of differentiation, separate regression models including 
either variable were compared using the Akaike Information Criterion (AIC) to identify the 
best model as having the lowest AIC value. Wald χ2 tests were used to assess statistical 
significance of cross-product terms for interactions between tumour EBV status and other 
independent variables. To further investigate heterogeneity by TNM stage, a stratified 
analysis was performed and the stratum-specific estimates pooled using random-effects 
meta-analysis. Between-group heterogeneity was assessed for statistical significance using 
the Q test and quantified with the I2 statistic as low (<25%), moderate (25–50%) or high 
(>50%).24
As a sensitivity analysis, we compared our aggregated analysis to a two-step approach.25 
First, study-specific HRs and 95% CIs of the association between tumour EBV status and 
mortality were estimated using multivariable Cox regression models. Second, the 13 study-
specific adjusted HRs for tumour EBV positivity were pooled using random-effects meta-
analysis. Heterogeneity by continent (Asia, Europe or America) was evaluated by meta-
regression.
A p value <0.05 was considered statistically significant for all tests except the Q test, for 
which p<0.10 was considered significant. All reported p values were two-sided. Statistical 
analyses were performed using SAS V.9.1 and Stata V.10.
RESULTS
Among the 13 case series, there were a total of 4599 patients with invasive gastric cancer 
(table 1). The mean age at diagnosis was 58 years (SD 12 years) and 71% were male. Most 
of the cancers were diagnosed at advanced stages (52% stages III or IV), localised to non-
cardia subsites (70%), and classified as Lauren intestinal-type (57%). There were 2247 
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(49%) deaths during a median of 3.0 (25th percentile, 1.1; 75th percentile, 5.5) years of 
follow-up.
Three hundred and seventy-five (8.2%) tumours were EBV-positive overall. In unadjusted 
logistic regression analyses, tumour EBV positivity was higher in early stage, cardia 
localisation, diffuse-type histology, poorer differentiation and men (figure 1). In a 
multivariable model including all significant variables, the OR per unit change in TNM 
stage was 0.79 (95% CI 0.69 to 0.91). Considered individually in multivariable models, each 
of the components of TNM stage was inversely associated with tumour EBV positivity 
(p=0.001 for tumour, p=0.02 for lymph nodes and p=0.004 for presence of metastasis). 
Furthermore, both tumour and metastasis, but not lymph nodes, remained significant in a 
mutually adjusted model.
In unadjusted Cox regression analyses, TNM stage was a strong predictor of mortality, with 
HRs (compared to stage I) of 3.1 for stage II, 8.1 for stage III and 13.2 for stage IV. Age, 
anatomic subsite, histological type and degree of differentiation were each significant 
prognostic indicators, whereas sex and year of diagnosis were not. Median survival time was 
8.5 years for patients with EBV-positive tumours and 5.3 years for those with EBV-negative 
tumours (log-rank test p=0.0006; figure 2).
In a multivariable model fitted for tumour EBV status, TNM stage, age, anatomic subsite 
and degree of differentiation, all variables were statistically significant predictors of 
mortality (figure 3). Specifically, advanced stage, older age and less differentiation were 
associated with worse prognosis. Compared to tumours localised to the cardia, tumours 
arising in non-cardia sites were associated with lower mortality, whereas tumours of 
overlapping subsites or post-gastrectomy remnants were associated with increased mortality. 
Adjusted for stage and the other potential confounders, EBV positivity was associated with 
lower mortality (HR 0.72; 95% CI 0.61 to 0.86). With the exclusion of the 915 (20%) cases 
that had missing data for one or more variables, the HR for EBV status was 0.71 (95% CI 
0.59 to 0.88). Furthermore, there were no significant multiplicative interactions between 
tumour EBV status and other independent variables (data not shown).
In an alternative model including histological type instead of degree of differentiation, HRs 
for tumour EBV status, stage, age and anatomic subsite were generally similar. Compared to 
patients with tumours classified as diffuse-type histology, those with mixed or unspecified 
histology had similar mortality, whereas patients with intestinal-type histology had a better 
prognosis (HR 0.81; 95% CI 0.74 to 0.89). In this alternative model, the adjusted HR for 
tumour EBV positivity was 0.74 (95% CI 0.62 to 0.88), but the AIC indicated that the fit 
was slightly inferior to the model including degree of differentiation.
Results from the two-step analyses were similar to the estimates derived from the aggregated 
analysis. The summary HR for tumour EBV positivity combining the 13 study-specific HRs 
was 0.71 (95% CI 0.56 to 0.91), with low heterogeneity among studies (I2=21%; p=0.2). 
Furthermore, there was no significant variation by continent (figure 4), with HRs for tumour 
EBV positivity of 0.73 for Asia, 0.48 for Europe and 0.92 for the Americas (p=0.4). 
Likewise, the summary HR for tumour EBV positivity combining the five stage-specific 
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HRs (ie, including unspecified stage) was 0.68 (95% CI 0.54 to 0.87), with only moderate 
heterogeneity among the stages (I2=33%; p=0.2).
DISCUSSION
In both aggregated and two-step adjusted analyses of 4599 gastric cancer cases, we found 
longer survival associated with tumour EBV positivity. Our study represents by far the 
largest cancer series addressing this association, and there was no substantial heterogeneity 
among the study populations. Our finding for EBV-positive tumours accords with the 
recognised survival advantage of lymphoepithelioma-like carcinoma (LELC),26 a rare 
histology subtype of gastric cancer that is typically EBV-associated.427 Previous studies of 
EBV’s prognostic significance in more common histologies of gastric cancer are limited by 
small numbers of EBV-positive tumours and/or inadequate accounting for key prognostic 
indicators; findings have been inconsistent, with some reporting a non-significant survival 
advantage for EBV-positive tumours,13172128–31 while others report a non-significant 
greater risk of death.101132
Our results are analogous to another virus-associated malignancy, human papillomavirus 
(HPV)-associated oropharyngeal cancer. HPV is found in a subset of lingual and palatine 
tonsil tumours and is associated with distinct clinical and biological characteristics, 
including favourable prognosis.33 Although Herpesviridae and Papillomaviridae are highly 
disparate virus families, common aspects of virus–host interaction may contribute to 
survival advantage.
The mechanisms underlying better survival of EBV-positive gastric cancers are uncertain. A 
potential immunological basis is the extensive infiltration of tumour nests with cytotoxic 
CD8 lymphocytes that may promote eradication of EBV-positive malignant cells.34–36 An 
alternative hypothesis is that genetic alterations potentially associated with better survival 
(eg, mutated ARID1A) may be more common in EBV-positive tumours.37 It is also possible 
that EBV-positive tumours may be more sensitive to chemotherapy-induced apoptosis, as 
reported in gastric LELC38 and EBV-associated Hodgkin lymphoma.39 Additional studies 
are warranted to test these various hypotheses and identify the determinants.
In our data, adjusted for other clinicopathological characteristics, there were inverse 
associations of tumour EBV positivity with TNM stage as well as its individual components. 
A meta-analysis by Lee et al5 found summary ORs of 0.75 (p=0.3) for TNM stage and 0.85 
(p=0.3) for lymph node spread. On the contrary, a meta-analysis by Li et al40 found a 
significant OR of 0.51 (p<0.05) for lymph node spread. Since stage is also associated with 
mortality, we decided to analyse this composite variable as a confounder. However, this 
approach may have underestimated the effect of EBV if the survival advantage is in fact 
mediated by lymph node spread and/or extent of the primary tumour.
Our data are consistent with previous reports that advanced TNM stage, older age, cardia 
tumour localisation, and less differentiated histology are adverse prognostic indicators.41–43 
Notably, several of our Asian case series were collected as part of screening programmes, 
which may explain the relatively longer survival as compared to population-based data.44 
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Nevertheless, this study characteristic would not bias evaluation of the association with 
tumour EBV status.
With respect to possible study limitations, although all 13 contributing series used AJCC 
classification, assessment of tumour, node and/or metastasis characteristics may not have 
been uniform. Furthermore, although overall mortality is considered a more robust outcome, 
cause-specific mortality would have been additionally informative for a secondary analysis. 
Lastly, our study also lacked information on treatment and co-morbidity history.
EBV has been detected in a number of lymphoproliferative disorders and carcinomas.45 
Regarding lymphoproliferative disorders, population-based studies and case series provide 
inconsistent results of EBV’s prognostic significance in Hodgkin lymphoma.46 However, 
Minnicelli et al47 reported a significant survival advantage of tumour EBV positivity and 
Levine et al48 reported higher survival with elevated antibody titres to the viral capsid 
antigen (VCA) in sporadic Burkitt lymphoma. Perhaps more relevant to gastric cancer, 
EBV-positive nasopharyngeal carcinoma has been found to have better prognosis as 
compared with EBV-negative cases,4950 in part because of better response to therapy.
Our findings on clinical prognosis provide additional evidence that EBV-positive gastric 
cancer may be a distinct disease entity. Several lines of evidence suggest an aetiological role 
for EBV in gastric carcinogenesis. EBV-positive gastric cancer exhibits uniform presence of 
monoclonal viral episomes in the tumour cells,6 implying the presence of EBV at the time of 
initial transformation and its requirement for maintenance of the transformed phenotype. 
EBV-positive gastric cancer also displays distinct clinical, genetic and demographic features 
as compared to EBV-negative cancer.72951–53 Interestingly, Tang et al54 found that 
compared to uninfected tumours, EBV-positive gastric cancer had significant upregulation 
of key cellular factors in pathways related to NFKB signalling and immune response. 
Although seropositivity against EBV infection is nearly ubiquitous in humans, elevated 
titres against VCA and EBV nuclear antigen (EBNA) have been shown to precede 
development of preneoplastic55 and neoplastic gastric lesions,5657 and have been associated 
with longer gastric cancer survival, particularly for cancers localised to the gastric cardia.58
In summary, this large analysis found that patients with EBV-positive gastric tumours have 
a significantly better outcome than those with EBV-negative tumours. Future studies should 
elucidate possible mechanisms underlying this protective association.
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Significance of this study
What is already known on this subject?
▸ While chronic Helicobacter pylori infection is the primary cause of gastric 
cancer, a subset of cases also contain Epstein–Barr virus (EBV) DNA.
▸ The viral genome in EBV-positive cases is monoclonal and present in all 
tumour cells, suggesting the virus may be a cofactor in gastric 
carcinogenesis.
▸ Patients with EBV-positive gastric tumours have distinct demographic, 
clinical and pathological features compared to those with EBV-negative 
tumours.
What are the new findings?
▸ EBV-positive gastric cancer tends to have lower tumour–node–metastasis 
(TNM) stage.
▸ Even adjusted for TNM stage as well as other prognostic indicators, tumour 
EBV positivity confers a relative survival advantage.
How might it impact on clinical practice in the foreseeable future?
▸ The difference in prognosis by tumour EBV status provides additional 
evidence that EBV-positive gastric cancer is a distinct disease entity.
▸ EBV-positive gastric cancer may warrant different preventive and/or 
therapeutic modalities.
▸ The mechanisms conferring better survival of EBV-positive tumours may 
lead to novel approaches to manage gastric cancer in general.
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ORs and 95% CIs for the associations of selected clinical and demographic characteristics 
with gastric tumour Epstein–Barr virus positivity.
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Kaplan–Meier estimated survival after gastric cancer diagnosis by tumour Epstein–Barr 
virus (EBV) status.
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HRs and 95% CIs for associations of tumour Epstein–Barr virus (EBV) status and other 
selected characteristics with overall mortality after gastric cancer diagnosis.
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Forest plot of HRs for the association of gastric cancer mortality with tumour Epstein–Barr 
virus (EBV) positivity for the study populations, by continent. Study-specific HRs are 
shown as squares, with the size of the symbol inversely proportional to the study specific 
variance. Summary random-effects HRs are shown as diamonds, with the middle 
corresponding to the point estimate and the width representing the 95% CIs.
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